Laboratory Animal Center and Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou, China.
CNS Neurosci Ther. 2022 Nov;28(11):1675-1688. doi: 10.1111/cns.13916. Epub 2022 Jul 13.
There might be more than 10 million confirmed cases of Parkinson's disease (PD) worldwide by 2040. However, the pathogenesis of PD is still unclear. Host health is closely related to gut microbiota, which are affected by factors such as age, diet, and exercise. Recent studies have found that gut microbiota may play key roles in the progression of a wide range of diseases, including PD. Changes in the abundance of gut bacteria, such as Helicobacter pylori, Enterococcus faecalis, and Desulfovibrio, might be involved in PD pathogenesis or interfere with PD therapy. Gut microbiota and the distal brain achieve action on each other through a gut-brain axis composed of the nervous system, endocrine system, and immune system. Here, this review focused on the current understanding of the connection between Parkinson's disease and gut microbiota, to provide potential therapeutic targets for PD.
到 2040 年，全球可能有超过 1000 万例帕金森病 (PD) 确诊病例。然而，PD 的发病机制仍不清楚。宿主健康与肠道微生物群密切相关，而肠道微生物群受到年龄、饮食和运动等因素的影响。最近的研究发现，肠道微生物群可能在多种疾病的进展中发挥关键作用，包括 PD。肠道细菌丰度的变化，如幽门螺杆菌、粪肠球菌和脱硫弧菌，可能与 PD 的发病机制有关，或干扰 PD 的治疗。肠道微生物群和远端大脑通过由神经系统、内分泌系统和免疫系统组成的肠脑轴相互作用。在这里，本综述重点介绍了目前对帕金森病与肠道微生物群之间联系的理解，为 PD 提供潜在的治疗靶点。
